Results 1 to 10 of about 8,834,434 (252)

Factors associated with changes in opioid analgesic prescribing after opioid agonist treatment initiation: A nationwide registry cohort study [PDF]

Drug and Alcohol Dependence Reports
Background: Pain is common among individuals receiving opioid agonist treatment (OAT). This study aims to investigate factors associated with changes in opioid analgesic dispensing among treatment-naïve patients initiating OAT.
Gabriela Rolova, Svetlana Skurtveit, Anne Bukten, Ingvild Odsbu, Desiree Eide   +4 more
doaj   +2 more sources

Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon

Harm Reduction Journal, 2017
Background Opioid agonist therapy has been widely used to reduce harms among individuals with opioid use disorder but its effectiveness has not been evaluated in the Middle East North African (MENA) region.
Ali Ghaddar, Zeinab Abbas, Ramzi Haddad
doaj   +2 more sources

What is the benefit of inconsistent opioid agonist treatment in patients with prescription opioid use disorder?

European Psychiatry, 2023
Introduction Studies consistently show that patients with prescription opioid use disorder (OUD) respond to buprenorphine treatment. Few studies have followed these patients in the long-term.
R. Weiss, M. L. Griffin
doaj   +1 more source

Opioid Substitution: More than Only Methadone!

European Psychiatry, 2022
Opioid misuse and its rising rates of morbidity and associated mortality is an increasing area of concern worldwide. The licit/illicit consumption of opioids ranging from plant-based substances and pharmaceutical drugs (particularly analgesia) to the new
M. Torrens
doaj   +1 more source

Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015–2018: a repeated cross-sectional analysis

BMJ Open, 2021
Objective To describe opioid agonist treatment prescribing rates in provincial prisons and compare with community prescribing rates.Design We used quarterly, cross-sectional data on the number and proportion of people prescribed opioid agonist treatment ...
Fiona Kouyoumdjian, Lori Kiefer, Susan Bondy, Claire Bodkin, Leonora Regenstreif   +4 more
doaj   +1 more source

Stimulant use disorder diagnosis and opioid agonist treatment dispensation following release from prison: a cohort study

Substance Abuse Treatment, Prevention, and Policy, 2022
Background Concurrent opioid and stimulant use is on the rise in North America. This increasing trend of use has been observed in the general population, and among people released from prison in British Columbia (BC), who face an elevated risk of ...
Heather Palis, Bin Zhao, Pam Young, Mo Korchinski, Leigh Greiner, Tonia Nicholls, Amanda Slaunwhite   +6 more
doaj   +1 more source

The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.

International Journal of Population Data Science, 2022
Objectives There are critical periods of mortality risk at onset and cessation of opioid agonist treatment. We aim to determine whether non-fatal overdose followed the same pattern as fatal overdose, comparing the first 4 weeks of treatment and ...
Nicola Jones, Louisa Degenhardt, Matthew Hickman, Suzanne Nielsen, Sarah Larney, Timothy Dobbins, Robert Ali   +6 more
doaj   +1 more source

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report

Harm Reduction Journal, 2021
Background For people with opioid use disorder who are not responding to oral opioid agonist treatment, evidence supports the effectiveness of injectable opioid agonist treatment with injectable hydromorphone (an opioid analgesic) and diacetylmorphine ...
Heather Palis, Scott MacDonald, Jennifer Jun, Eugenia Oviedo-Joekes   +3 more
doaj   +1 more source

Ligand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonist [PDF]

, 2013
Since the discovery of the endomorphins (EM), the postulated endogenous peptide agonists of the mu-opioid receptors, several analogues have been synthesized to improve their binding and pharmacological profiles.
Murányi Marianna, Szűcs, Mária, Dochnal Roberta, Kicsi Emese, Kicsi, Emese Gabriella, Fábián Gabriella, Szabó Gyula, Szabó, Gyula, Zentai, András, Bozó, Beáta, Fábián, Gabriella, Birkás Erika, Cinar Resat, Bozó Bea, Birkás, Erika, Kékesi Orsolya Sára, Cinar, Resat, Tóth, Géza, Mácsai Mónika, Mácsai, Mónika, Kékesi, Orsolya, Dochnal, Roberta Beatrix, Tóth Géza, Szűcs Mária, Murányi, Marianna, Zentai András   +25 more
core   +2 more sources

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study

Systems, 2023
Modified opioid agonist therapy (OAT) guidelines that were initially introduced during the COVID-19 pandemic allow prescribers to increase the number of take-home doses to fulfill their need for physical distancing and prevent treatment discontinuation ...
Narjes Shojaati, Nathaniel D. Osgood
doaj   +1 more source